NCT07637110 Dry Weight Reduction Intervention Via Extra Ultrafiltration
| NCT ID | NCT07637110 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Fluid Accumulation |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-09-10 |
| Primary Completion | 2030-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2026-09-10 with a primary completion date of 2030-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations. This trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.
Eligibility Criteria
Inclusion Criteria: * Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either: 1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered. OR 2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \<75. Exclusion Criteria: * Age \<18 years * Receiving hemodialysis treatments for acute kidney injury * Receiving hemodialysis treatments for less than four weeks * Planned switch to peritoneal or home dialysis within next three months * Current or planned incremental hemodialysis (less than 3 treatments per week) * Current or planned intensive hemodialysis (four or more treatments per week) * Scheduled kidney transplantation * Major cardiovascular or bleeding event within previous 90 days * Receiving chemotherapy or radiation treatment for cancer * History of cirrhosis with ascites * Inability to complete 24-hour ambulatory blood pressure measurement * Wheelchair dependance or other inability to complete six-minute walk test * Pre-dialysis systolic blood pressure \<100 mmHg * Scheduled use of midodrine with hemodialysis treatments * History of non-adherence with dialysis treatments * Pregnancy * Institutionalized * Current or pending enrollment in hospice care * Inappropriate for enrollment based on investigator or nephrologist discretion
Contact & Investigator
Bryan Kestenbaum, MD, MS
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT07637110 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Fluid Accumulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07637110 currently recruiting?
Yes, NCT07637110 is actively recruiting participants. Contact the research team at lrios1@uw.edu for enrollment information.
Where is the NCT07637110 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07637110 clinical trial?
NCT07637110 is sponsored by University of Washington. The principal investigator is Bryan Kestenbaum, MD, MS at University of Washington. The trial plans to enroll 120 participants.